Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

Fig. 3

Progression-free survival (PFS) in cervical carcinoma patients. PFS based on a lymph node metastasis (p = 0.20), b number of lymph node metastases (p = 0.01), cUGT1A1 genotype (p = 0.20), and dUGT1A1 genotype in patients with ≤1 metastatic lymph node (p = 0.02). UTG1A1: uridine diphosphate glucuronosyltransferase 1A1; p < 0.05*

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us